-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, VIQtUNmsPfPHOf/YABukzu/y7YOi2P/zJ3xkmIHde5uBAtxbrDKNm259iYF5ZB2u iOSNaGqcLdn2kRG+yTiEBA== 0001116502-01-501572.txt : 20020412 0001116502-01-501572.hdr.sgml : 20020412 ACCESSION NUMBER: 0001116502-01-501572 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20011210 ITEM INFORMATION: Changes in registrant's certifying accountant ITEM INFORMATION: Financial statements and exhibits FILED AS OF DATE: 20011212 FILER: COMPANY DATA: COMPANY CONFORMED NAME: BIOSPECIFICS TECHNOLOGIES CORP CENTRAL INDEX KEY: 0000875622 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 113054851 STATE OF INCORPORATION: DE FISCAL YEAR END: 0131 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-19879 FILM NUMBER: 1812402 BUSINESS ADDRESS: STREET 1: 35 WILBUR ST CITY: LYNBROOK STATE: NY ZIP: 11563 BUSINESS PHONE: 5165937000 MAIL ADDRESS: STREET 1: 35 WILBUR STREET CITY: LYNBROOK STATE: NY ZIP: 11563 8-K 1 biospecifics-8k.txt CURRENT REPORT SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 (d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 10, 2001 BioSpecifics Technologies Corp. (Exact name of registrant as specified in its charter) - -------------------------------------------------------------------------------- Delaware 0-19879 11-3054851 - -------------------------------------------------------------------------------- (State or other (Commission (IRS Employer - -------------------------------------------------------------------------------- jurisdiction of File No.) Identification No.) - -------------------------------------------------------------------------------- incorporation) - -------------------------------------------------------------------------------- 35 Wilbur Street, Lynbrook, New York 11563 (Address of principal executive offices) (Zip Code) Registrant's telephone number, including area code: (516) 593-7000 Not Applicable (Former name or former address, if changed since last report) Item 4. Changes in Registrant's Certifying Accountant - ------- --------------------------------------------- Grant Thornton LLP was previously the principal accountants for BioSpecifics Technologies Corp. ("the Registrant"). On December 10, 2001, that firm's appointment as principal accountants was terminated by the Registrant and BDO Seidman, LLP was engaged as principal accountants. The decision to change accountants was approved by the Board of Directors of the Registrant. In connection with the audits of the two fiscal years ended January 31, 2001, and the subsequent interim period through December 10, 2001, there were no disagreements with Grant Thornton LLP on any matter of accounting principles or practices, financial statement disclosure, or auditing scope or procedures, which disagreements if not resolved to their satisfaction would have caused them to make reference in connection with their opinion to the subject matter of the disagreement. The audit reports of Grant Thornton LLP on the consolidated financial statements of the Registrant as of and for the years ended January 31, 2000 and January 31, 2001, did not contain any adverse opinion or disclaimer of opinion, nor were they qualified or modified as to uncertainty, audit scope, or accounting principles. A letter from Grant Thornton LLP is attached as Exhibit 16 to this Form 8-K. Item 7. Financial Statements, Pro Forma Financial Information and Exhibits - ------- ------------------------------------------------------------------ (c) Exhibits 16. Letter of Grant Thornton LLP dated December 11, 2001 SIGNATURE Pursuant to the requirements of the Securities and Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. BioSpecifics Technologies Corp. By: /s/ Albert Horcher Albert Horcher Secretary, Treasurer, Principal Financial and Chief Accounting Officer Dated: December 12, 2001 EX-16 3 ex-16.txt LETTER RE: CHANGE OF CERTIFYING ACCOUNTANT Exhibit 16 December 11, 2001 Securities and Exchange Commission Washington, D.C. 20549 Re: BioSpecifics Technologies Corp. File No. 0-19879 Dear Sir or Madam: We have read Item 4 of the Form 8-K of BioSpecifics Technologies Corp. dated December 10, 2001 and agree with the statements concerning our Firm contained therein. Very truly yours, Grant Thornton LLP Melville, NY -----END PRIVACY-ENHANCED MESSAGE-----